EuroPCR 24: 1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II

Published: 22 May 2024

  • Views:

    Views Icon 248
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.

Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT followed by 5-month Ticagrelor monotherapy in patients with acute coronary syndromes with DCB.


  1. What is the existing evidence supporting low-intensity antiplatelet regimen?
  2. What question does this trial aim to address?
  3. What was the design, eligibility criteria, and outcome measures?
  4. What were the baseline characteristics of the randomized patients?
  5. What are the key findings?
  6. What are the implications for practice?
  7. What further research is required?

Recorded on-site at EuroPCR, 2024.


You must be to comment. If you are not registered, you can register here.